BLOOD 2022: Axi-Cel Superior to Standard of Care as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma
Researchers say axi-cel should replace chemoimmunotherapy as second-line standard of care for early relapsed/refractory LBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.